STABLY ENGINEREED PROTEASOME INHIBITOR RESISTANT IMMUNE CELLS FOR IMMUNOTHERAPY
展开▼
机译:STANLEY工程化的针对免疫疗法的抗癌免疫细胞
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to gene editing methods to engineer primary immune cells that are made resistant to proteasome inhibitors, such as Bortezomib, Carfilzomib, Ixazomib, Marizomib, Delanzomib or Oporozomib, for their use in cell immunotherapy in combination with proteasome inhibitor treatments.
展开▼